Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor –induced gastroenterocolitis
Immune checkpoint inhibitor –induced gastroenterocolitis (ICI-GEC) represents one of the common and severe side-effects of immunotherapy, impacting 7–30% of treated patients [1]. Current guidelines recommend systemic corticosteroids for moderate to severe cases of ICI-GEC, but whether these therapies have a dose- or time-d ependent impact on patients' survival outcomes remains unclear [2,3]. Murine data underscore the pleiotropic immunosuppressive effects of corticosteroids, but the clinical implications of these effects in the context of checkpoint blockade remain under-investigated [4].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Leah L. Thompson, Ethan Katznelson, Donna E. Leet, Sienna M. Durbin, Jaewon Yoon, Kerry L. Reynolds, Michael L. Dougan, Steven T. Chen Tags: Letter to the Editor Source Type: research